---
title: 'The role of the thioredoxin/thioredoxin reductase system in the metabolic
  syndrome: towards a possible prognostic marker?'
type: pub
encoding: UTF-8

---
<h1>Publikasjon</h1>
<article id="csl-bib-container-UGFCQMVP" class="csl-bib-container">
  <div class="csl-bib-body"> <div class="csl-entry">Tinkov, A. A., Bjørklund, G., Skalny, A. V., Holmgren, A., Skalnaya, M. G., Chirumbolo, S., &#38; Aaseth, J. (2018). The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker? <i>Cellular and Molecular Life Sciences (CMLS)</i>, <i>75</i>(9), 1567–1586. <a href="https://doi.org/10.1007/s00018-018-2745-8">https://doi.org/10.1007/s00018-018-2745-8</a></div> </div>
  <div class="csl-bib-buttons">
    <a href="#taxonomy-article-UGFCQMVP" alt="archive" class="csl-bib-button">Arkiv</a>
    <a href="https://app.cristin.no/results/show.jsf?id=1581022" alt="Cristin" class="csl-bib-button">Cristin</a>
    <a href="http://zotero.org/groups/5881554/items/UGFCQMVP" alt="Zotero" class="csl-bib-button">Zotero</a>
    <a href="#keywords-article-UGFCQMVP" alt="keywords" class="csl-bib-button">Emneord</a>
    <a href="#about-article-UGFCQMVP" alt="about_pub" class="csl-bib-button">Om</a>
    <a href="#sdg-article-UGFCQMVP" alt="sdg" class="csl-bib-button">Berekraftsmål</a>
    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105605" alt="Unpaywall" class="csl-bib-button">Unpaywall</a>
    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105605" alt="EZproxy" class="csl-bib-button">EZproxy</a>
  </div>
  <div id="csl-bib-meta-container-UGFCQMVP"></div>
</article>
<div id="csl-bib-meta-UGFCQMVP" class="csl-bib-meta">
  <article id="about-article-UGFCQMVP" class="about_pub-article">
    <h1>Om</h1>
    Tinkov et al. gjennomførte ein gjennomgang som utforskar rolla til thioredoxin/thioredoxin reduktase (Trx/TrxR)-systemet i metabolsk syndrom, ein samling av tilstandar som aukar risikoen for hjartesjukdom, diabetes og slag. Dei fann at dette systemet, som involverer protein som hjelper med cellulære reaksjonar, er avgjerande for prosessar som funksjon av feittvev, karbohydratmetabolisme, insulinproduksjon, blodtrykkskontroll og inflammasjon. Studien antyder at det å målrette Trx/TrxR-systemet kan vere nyttig i handteringa av metabolsk syndrom, insulinresistens, type 2 diabetes, hypertensjon og åreforkalkning. I tillegg foreslår forfattarane at dette systemet kan tene som ein markør for å forutsjå eller diagnostisere metabolsk syndrom, og tilby ein potensiell ny reiskap for helsepersonell.
  </article>
  <article id="keywords-article-UGFCQMVP" class="keywords-article">
    <h1>Emneord</h1>
    Thioredoxin Reduktase, Metabolsk Syndrom, Insulinresistens, Type 2 Diabetes, Hypertensjon, Åreforkalkning
  </article>
  <article id="abstract-article-UGFCQMVP" class="abstract-article">
    <h1>Samandrag</h1>
    Mammalian thioredoxin reductase (TrxR) is a selenoprotein with three existing isoenzymes (TrxR1, TrxR2, and TrxR3), which is found primarily intracellularly but also in extracellular fluids. The main substrate thioredoxin (Trx) is similarly found (as Trx1 and Trx2) in various intracellular compartments, in blood plasma, and is the cell’s major disulfide reductase. Thioredoxin reductase is necessary as a NADPH-dependent reducing agent in biochemical reactions involving Trx. Genetic and environmental factors like selenium status influence the activity of TrxR. Research shows that the Trx/TrxR system plays a significant role in the physiology of the adipose tissue, in carbohydrate metabolism, insulin production and sensitivity, blood pressure regulation, inflammation, chemotactic activity of macrophages, and atherogenesis. Based on recent research, it has been reported that the modulation of the Trx/TrxR system may be considered as a new target in the management of the metabolic syndrome, insulin resistance, and type 2 diabetes, as well as in the treatment of hypertension and atherosclerosis. In this review evidence about a possible role of this system as a marker of the metabolic syndrome is reported.
  </article>
  <article id="sdg-article-UGFCQMVP" class="sdg-article">
    <h1>Berekraftsmål</h1>
    <div class="sdg-container"><div id="sdg3" class="sdg">
        <img src="{{< params subfolder >}}images/sdg/sdg03_nn.png" class="image" alt="SDG 3">
        <div class="sdg-overlay">
          <a href="/nn/archive/?key=?sdg=3#archive" class="sdg-publication-count"><span>1358</span> publikasjonar</a>
          <p><a href="https://fn.no/om-fn/fns-baerekraftsmaal/god-helse-og-livskvalitet?lang=nno-NO" class="sdg-read-more">Les meir</a></p>
        </div>
      </div></div>
  </article>
  <article id="taxonomy-article-UGFCQMVP" class="taxonomy-article">
    <h1>Arkiv</h1>
    <ul>
      <li>
        <a href="/nn/archive/?key=3DCRN523">Universitetet i Innlandet</a>
      </li>
      <li>
        <a href="/nn/archive/?key=IDKFS3MX">Fakultet for helse- og sosialvitenskap</a>
      </li>
      <li>
        <a href="/nn/archive/?key=GTV4ECMZ">Institutt for helse- og sykepleievitenskap</a>
      </li>
      <li>
        <a href="/nn/archive/?key=676HMQBA">2018</a>
      </li>
      <li>
        <a href="/nn/archive/?key=JSBENWRD">April</a>
      </li>
    </ul>
  </article>
</div>
